BioCentury

7:00 AM GMT, Sep 13, 2010
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Product Development

Combination hesitation

Idenix Pharmaceuticals Inc. and competing companies developing combinations of direct antivirals to treat HCV all agreed that the side effects seen in a Phase I trial of two of the biotech's antivirals are compound-specific. The setback thus won't dampen interest in replacing interferon-based regimens with an all-oral cocktail of direct antivirals as the standard of care.

Last week, FDA placed IDX184 and IDX320 on hold after Idenix saw liver abnormalities in a Phase I trial combining the two agents alone.

Despite the setback, direct antiviral agents - small molecules that target viral proteins to block replication - are the future of HCV therapy, according to Raymond Chung, director of hepatology at Harvard Medical School.

"Even with the introduction of telaprevir and boceprevir next year as add-ons to interferon-based therapy, this is not going to move the needle substantially in terms of providing treatment for

Read the full 1413 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.